• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Zealand Pharma

321.20 DKK-5.86 %14.8. klo 17.59
Less than 1K followers

ZEAL

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-5.86 %
+14.35 %
+3.41 %
-19.64 %
-31.13 %
-5.83 %
+34.96 %
+88.72 %
+304.03 %

Zealand Pharma operates in biotechnology. Special focus is found in the development of drugs for the treatment of diabetes and various intestinal diseases. The company has a varied product portfolio with separate brands that are sold on a global level. The largest operations are in the Nordic market. Zealand Pharma was founded in 1997 and is headquartered in Søborg, Denmark.

Read more
Market cap
22.99B DKK
Turnover
189.02M DKK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
12.11.
2026

Interim report Q3'26

All
Research
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Analyst Comment13.08.2026 klo 08.19

HCA Red Flag: Zealand Pharma earns BDKK 3.9, but still burns cash (AI)

Expect a weak opening: the pre-tax profit of DKK 4,006 million DKK exceeded the expected MDKK 3,782. DKK alone, because Zealand Pharma spent MDKK 632 DKK vs. 789 MDKK DKK on petrelintide trials that have not yet started. Guidance was maintained, and a royalty sale adds approximately DKK 640M. DKK.

Zealand Pharma
Regulatory press release13.08.2026 klo 08.00

Zealand Pharma Announces Financial Results for the First Half of 2026

Zealand Pharma
Regulatory press release12.08.2026 klo 23.05

Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide

Zealand Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release10.08.2026 klo 18.00

Zealand Pharma - Transactions related to share buy-back program (week 32, 2026)

Zealand Pharma
Regulatory press release03.08.2026 klo 18.00

Zealand Pharma - Transactions related to share buy-back program (week 31, 2026)

Zealand Pharma
Regulatory press release27.07.2026 klo 18.00

Zealand Pharma - Transactions related to share buy-back program (week 30, 2026)

Zealand Pharma
Regulatory press release20.07.2026 klo 23.00

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Zealand Pharma
Regulatory press release20.07.2026 klo 18.00

Zealand Pharma: Transactions related to share buy-back program (week 29, 2026)

Zealand Pharma
Regulatory press release13.07.2026 klo 18.00

Zealand Pharma - Transactions related to share buy-back program (week 28, 2026)

Zealand Pharma
Regulatory press release06.07.2026 klo 18.00

Zealand Pharma - Transactions related to share buy-back program (week 27, 2026)

Zealand Pharma
Regulatory press release30.06.2026 klo 23.01

Total number of shares and voting rights in Zealand Pharma as of June 30, 2026

Zealand Pharma
Regulatory press release30.06.2026 klo 23.00

Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.

Zealand Pharma
Regulatory press release29.06.2026 klo 18.00

Zealand Pharma - Transactions related to share buy-back program (week 26, 2026)

Zealand Pharma
Regulatory press release22.06.2026 klo 23.00

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Zealand Pharma
Regulatory press release22.06.2026 klo 18.00

Zealand Pharma - Transactions related to share buy-back program (week 25, 2026)

Zealand Pharma
Regulatory press release15.06.2026 klo 18.00

Zealand Pharma - Transactions related to share buy-back program (week 24, 2026)

Zealand Pharma
Regulatory press release10.06.2026 klo 23.00

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Zealand Pharma
Regulatory press release08.06.2026 klo 18.05

Zealand Pharma - Transactions related to share buy-back program (week 23, 2026)

Zealand Pharma
Regulatory press release08.06.2026 klo 18.00

Zealand Pharma increases its share capital as a result of the exercise of employee warrants

Zealand Pharma
Regulatory press release07.06.2026 klo 21.30

Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis

Zealand Pharma